chemotherapy-induced acral erythema

Hand-foot label context

Record whether the source uses acral erythema, hand-foot syndrome or palmar-plantar erythrodysesthesia and whether it explicitly attributes the condition to chemotherapy.

1. What term did the clinician or source use, and what manifestations did that term denote? definition
2. Who assigned the label, when, and with what stated confidence? provenance

Alternative or coexisting process

Record evidence considered for hand-foot skin reaction, neuropathy, dermatitis, infection and other relevant explanations, allowing coexistence.

1. Which observations favour chemotherapy-induced acral erythema over each plausible alternative? boundary
2. Which findings require a coexisting diagnosis or further clinical assessment? action

Episode-linked administrations

Link implicated agents, formulations and administration records to the earliest reported symptoms and subsequent changes.

1. Which chemotherapy agents and formulations were actually administered before onset? provenance
2. How many days separated treatment initiation, recent administrations and the first acral symptoms? measurement

Attribution evidence and confounders

Capture the proposed culprit, competing exposures and symptom changes after treatment changes that occurred for clinical reasons.

1. What evidence supports the proposed culprit, and what competing drugs or local exposures remain plausible? boundary
2. If treatment was interrupted or resumed, what happened to the acral symptoms and what else changed concurrently? provenance

Site-specific skin observations

Record each affected palm or sole, symmetry, focality, colour relative to baseline and skin-surface changes.

1. Which surfaces are affected, and are changes diffuse, pressure-localised, symmetric or asymmetric? measurement
2. What changes from the person's baseline skin appearance and texture are documented at each site? measurement

Acral symptom sequence

Capture pain, burning, tingling or numbness, including their sequence and relationship to walking or hand use.

1. Which sensations preceded, accompanied or persisted after the visible skin changes? measurement
2. How do symptom location and intensity differ at rest and during specific activities? measurement

Task limitation evidence

Record effects on walking, grasping, dressing, washing and other relevant tasks, then preserve the clinician's grading rationale.

1. Which tasks are painful, restricted or dependent on assistance compared with baseline? measurement
2. Which grading system and version were used, and what observations support the assigned grade? provenance

Complication review triggers

Record open skin, worsening pain, impaired mobility or systemic symptoms and the clinical response they prompted, without assuming their cause.

1. Are blistering, fissures, ulceration or other skin-barrier defects present, and where? measurement
2. Do new local or systemic findings require urgent review under the patient's oncology instructions? action

Care plan and regimen decision

Record prescribed skin care, symptom relief, activity advice and any clinician-directed chemotherapy change, with the applicable guidance.

1. What episode-specific care was recommended, by whom, and using which drug- or regimen-specific guidance? provenance
2. What clinician-approved action and reassessment criteria apply to continuing, interrupting or modifying treatment? action

Longitudinal acral outcome

Compare follow-up observations with the episode baseline and document recovery criteria, residual impairment and subsequent flares.

1. How have skin findings, pain and task performance changed since the previous assessment? measurement
2. What documented recovery interval distinguishes a new episode from persistence or worsening of the existing episode? boundary

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these check these first hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these identifiers and schemes hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Standards and regulation

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these standards and regulation hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these real-world use hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these typical measurements hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these failure modes and hazards hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of chemotherapy-induced acral erythema this model covers, and on what evidence? provenance